Press release
Immune Thrombocytopenia Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GSK
The Key Immune Thrombocytopenia Purpura Companies in the market include - Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others.DelveInsight's "Immune Thrombocytopenia Purpura Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Immune Thrombocytopenia Purpura, historical and forecasted epidemiology as well as the Immune Thrombocytopenia Purpura market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Immune Thrombocytopenia Purpura market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Immune Thrombocytopenia Purpura Market Forecast [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Immune Thrombocytopenia Purpura Market Report:
*
The Immune Thrombocytopenia Purpura market size was valued ~USD 3,000 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In June 2024, Takeda (TSE:4502/NYSE:TAK) has shared positive findings from its Phase 2b randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and efficacy of mezagitamab (TAK-079) in treating persistent or chronic primary immune thrombocytopenia (ITP). ITP, a rare immune-mediated bleeding disorder, is marked by accelerated platelet destruction, leading to reduced platelet counts and increased bleeding risks. The results (Abstract #LB 01.1) were presented during the Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to launch a global Phase 3 trial for mezagitamab in ITP patients in the second half of FY2024.
*
In March 2024, Argenx announced that VYVGART (efgartigimod alfa) has been approved in Japan for the treatment of adults with Primary Immune Thrombocytopenia.
*
In 2023, the United States held the largest share of the Immune Thrombocytopenia treatment market in the 7MM, exceeding USD 1,870 million in market size
*
In 2024, Japan's total market size for Immune Thrombocytopenia (ITP) was approximately USD 200 million, and it is anticipated to grow by 2034.
*
In the 7MM, the US had the highest number of prevalent ITP cases, with approximately 66,500 cases in 2023. This number is anticipated to rise throughout the forecast period.
*
The prevalence of the condition is significantly higher among adults compared to children.
*
In 2023, the US had approximately 20,600 diagnosed prevalent cases among males and around 35,000 cases among females.
*
Key Immune Thrombocytopenia Purpura Companies: Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others
*
Key Immune Thrombocytopenia Purpura Therapies: BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others
*
The Immune Thrombocytopenia Purpura epidemiology based on gender analyzed that the majority of cases of ITP are found in females as compared to the male population.
*
The Immune Thrombocytopenia Purpura market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Immune Thrombocytopenia Purpura pipeline products will significantly revolutionize the Immune Thrombocytopenia Purpura market dynamics.
Immune Thrombocytopenia Purpura Overview
Immune Thrombocytopenia Purpura (ITP) is a rare autoimmune disorder where the immune system mistakenly attacks and destroys platelets, which are essential for blood clotting. This leads to low platelet counts, causing symptoms such as easy bruising, prolonged bleeding, petechiae (small red or purple spots on the skin), and in severe cases, internal bleeding. ITP can be either acute, often affecting children, or chronic, more common in adults. Treatment typically focuses on managing symptoms and may include corticosteroids, immunoglobulin therapy, or in some cases, splenectomy.
Get a Free sample for the Immune Thrombocytopenia Purpura Market Report:
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market [https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Immune Thrombocytopenia Purpura Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Immune Thrombocytopenia Purpura Epidemiology Segmentation:
The Immune Thrombocytopenia Purpura market report proffers epidemiological analysis for the study period 2020-20344 in the 7MM segmented into:
*
Total Prevalence of Immune Thrombocytopenia Purpura
*
Prevalent Cases of Immune Thrombocytopenia Purpura by severity
*
Gender-specific Prevalence of Immune Thrombocytopenia Purpura
*
Diagnosed Cases of Episodic and Chronic Immune Thrombocytopenia Purpura
Download the report to understand which factors are driving Immune Thrombocytopenia Purpura epidemiology trends @ Immune Thrombocytopenia Purpura Epidemiology Forecast [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Thrombocytopenia Purpura market or expected to get launched during the study period. The analysis covers Immune Thrombocytopenia Purpura market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Immune Thrombocytopenia Purpura Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Immune Thrombocytopenia Purpura Therapies and Key Companies
*
BT-595 (IgG Next Generation): Biotest
*
Efgartigimod (ARGX-113): Argenx
*
Rilzabrutinib(PRN-1008): Sanofi/ Principia Biopharma
*
Fostamatinib disodium: Rigel Pharmaceuticals
*
PRN1008: Principia Biopharma
*
LGD-4665: GlaxoSmithKline
*
Octagam 10%: Octapharma
*
Sym001: Symphogen A/S
*
R788: Kissei Pharma
*
BMS-986004: BMS-986004
*
Eltrombopag: GlaxoSmithKline
*
Romiplostim: Amgen
*
Hetrombopag Olamine: Jiangsu HengRui Medicine
*
Rituxan, Cyclophosphamide, Vincristine, Prednisone: Genentech, Inc.
*
Methylprednisolone and IVIG: Bayer
*
rituximab [MabThera/Rituxan]: Hoffmann-La Roche
*
PG2: PhytoHealth Corporation
Discover more about therapies set to grab major Immune Thrombocytopenia Purpura market share @ Immune Thrombocytopenia Purpura Treatment Market [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Immune Thrombocytopenia Purpura Market Strengths
*
The increasing number of product launches, coupled with advancements in betterment of existing products will fuel the growth.
*
Higher adaptation and cost-effectiveness of corticosteroid drugs segment will hold the significant share in developed countries
*
Increased acceptance of TPO-RA as a second line of treatment will boost the growth.
*
Rising prevalence of the ITP worldwide and increasing awareness of the disease in the 7MM will drive the market growth during the forecast period.
Immune Thrombocytopenia Purpura Market Opportunities
*
The pipeline of Immune Thrombocytopenia is robust with the involvement of major players, such as BMS, Amgen, Protalex, Squibb,and others.
Scope of the Immune Thrombocytopenia Purpura Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Immune Thrombocytopenia Purpura Companies: Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others
*
Key Immune Thrombocytopenia Purpura Therapies: BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others
*
Immune Thrombocytopenia Purpura Therapeutic Assessment: Immune Thrombocytopenia Purpura current marketed and Immune Thrombocytopenia Purpura emerging therapies
*
Immune Thrombocytopenia Purpura Market Dynamics: Immune Thrombocytopenia Purpura market drivers and Immune Thrombocytopenia Purpura market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Immune Thrombocytopenia Purpura Unmet Needs, KOL's views, Analyst's views, Immune Thrombocytopenia Purpura Market Access and Reimbursement
To know more about Immune Thrombocytopenia Purpura companies working in the treatment market, visit @ Immune Thrombocytopenia Purpura Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Immune Thrombocytopenia Purpura Market Report Introduction
2. Executive Summary for Immune Thrombocytopenia Purpura
3. SWOT analysis of Immune Thrombocytopenia Purpura
4. Immune Thrombocytopenia Purpura Patient Share (%) Overview at a Glance
5. Immune Thrombocytopenia Purpura Market Overview at a Glance
6. Immune Thrombocytopenia Purpura Disease Background and Overview
7. Immune Thrombocytopenia Purpura Epidemiology and Patient Population
8. Country-Specific Patient Population of Immune Thrombocytopenia Purpura
9. Immune Thrombocytopenia Purpura Current Treatment and Medical Practices
10. Immune Thrombocytopenia Purpura Unmet Needs
11. Immune Thrombocytopenia Purpura Emerging Therapies
12. Immune Thrombocytopenia Purpura Market Outlook
13. Country-Wise Immune Thrombocytopenia Purpura Market Analysis (2020-2034)
14. Immune Thrombocytopenia Purpura Market Access and Reimbursement of Therapies
15. Immune Thrombocytopenia Purpura Market Drivers
16. Immune Thrombocytopenia Purpura Market Barriers
17. Immune Thrombocytopenia Purpura Appendix
18. Immune Thrombocytopenia Purpura Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immune-thrombocytopenia-purpura-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-biotest-argenx-sanofi-principia-biopharma-rigel-pharma-principia-biopharma-gsk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune Thrombocytopenia Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GSK here
News-ID: 4013894 • Views: …
More Releases from ABNewswire

Lone Wolf Siding Emerges as the Best Siding Company in New Orleans Offering Prem …
Lone Wolf Siding is the best siding company in New Orleans, Louisiana.
Image: https://www.abnewswire.com/upload/2025/09/3522ab792132a4d3ddba57316984a0de.jpg
Lone Wolf Siding, a trusted siding contractor in New Orleans, proudly announces its expanded offerings designed to protect and enhance homes across Louisiana. With a strong foundation in expert siding installation and repair, the company now provides homeowners with a full suite of exterior solutions, including patios and pergolas, all backed by exceptional craftsmanship and a 100% satisfaction…

Buerger's Disease Pipeline 2025: Pioneering Clinical Developments by 3+ Global L …
DelveInsight's, "Buerger's Disease - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Buerger's Disease increasingly affects populations worldwide and is linked…

Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical Progress by 8+ Glob …
DelveInsight's, "Mucopolysaccharidosis III - Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Mucopolysaccharidosis III pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Mucopolysaccharidosis III (MPS III) is emerging as a significant global…

Ovarian Cancer Clinical Trials, Companies, Therapeutic Assessment, Emerging Ther …
Ovarian Cancer companies are Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.
Ovarian Cancer Pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analyzes DelveInsight.
Ovarian Cancer Overview:
Ovarian cancer is the deadliest gynecological cancer and the…
More Releases for Immune
Immune Probiotic Supplement Market Reviews: What Works Best for Gut and Immune S …
The Global Immune Probiotic Supplement Market reached US$ 68.73 Billion in 2024 and is projected to witness lucrative growth by reaching up to US$ 133.08 Billion by 2032. The Global Immune Probiotic Supplement Market is expected to exhibit a CAGR of 8.61% during the forecast period 2024-2032.
Immune Probiotic Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges.…
Decoding the Immune System: Immune Repertoire Sequencing Market Unleashes Insigh …
The Immune Repertoire Sequencing Market is likely to grow voraciously, i.e. at a CAGR of 7.3% between 2018-2026. Augmented and virtual reality are abreast with advanced technologies on a significant count. VR and AR do have loads of potential for offering in the healthcare vertical. The application areas include surgery and training simulation, and patients care and treatment.
Persistence Market Research (PMR) delivers the key insights on the immune repertoire sequencing…
Immune health supplement Market - Guardian of health: Supporting immune strength …
Newark, New Castle, USA: The "Immune health supplement Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Immune health supplement Market: https://www.growthplusreports.com/report/immune-health-supplement-market/7978
This latest report researches the industry structure,…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports.
Immune Health Supplements refer to the product which could improve human immune health.
The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
Learn more Through Sample Report…